SLC5A2 and hydrops fetalis: Additionally, the CANONICAL, EMPEROR-PRESERVED, and DELIVER trials were initiated to evaluate the effect of SGLT2 inhibition in HF with preserved ejection fraction (HfpEF) [33,34,35].